
ALK is now positioned to file for Chinese regulatory approval of its tablet Acarizax, a dust mite allergy treatment, following the issue of a waiver by country’s health authorities, a company press release announced on Thursday.
”In preparation for this application, ALK has completed a phase I trial in China and had initiated a phase III local registration trial in adult allergic rhinitis. However, the phase III trial has been paused since 2020 as a consequence of the Covid pandemic,” ALK writes in the statement.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app